News | July 20, 2010

New System Demonstrates Potential for CAD Patient Triage


July 20, 2010 – Rcadia Medical Imaging recently presented five studies demonstrating the potential of its COR Analyzer System to help rule out significant coronary artery stenosis in patients at low to intermediate risk of coronary artery disease (CAD) undergoing coronary computer tomography angiography (CTA). The ability to rule out disease and speed clinical decision making has great potential to reduce unneeded hospital costs, as well as improve patient care by allowing clinicians to focus on high priority patients. The studies were presented at the Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography in Las Vegas.

Triage of suspected CAD patients represents a major clinical and healthcare economic challenge in the United States. An estimated six million patients enter the emergency room in the United States each year with chest pain. Because current diagnostic techniques are often equivocal, an estimated two million, primarily low risk patients, are admitted to the hospital for further testing at an annual cost of $10-$13 billion. In an estimated 85 percent of these patients, an acute coronary event is subsequently ruled out.

In these studies, the COR Analyzer demonstrated high negative predictive values, exceeding 97 percent in four, meaning that more than 97 percent of patients determined by the COR Analyzer System to not have significant stenosis were in agreement with a “gold standard” comparator. The COR Analyzer software interprets CTA images in real time, with no human interaction to provide an immediate indication of whether a patient has significant (50 percent or more) stenosis.

In a multi-center study led by researchers at Stony Brook University Medical Center in Stony Brook, N.Y., researchers evaluated CTA studies with the COR Analyzer from 341 patients from low, intermediate and high prevalence populations.

“Results suggest that [the COR Analyzer] can be used in clinical practice to facilitate the accurate detection and exclusion of CAD on 64-slice and over CT scanners,” said Michael Poon, M.D., director, advanced cardiac imaging, department of radiology, Stony Brook Medical Center. The COR Analyzer results “do not replace the expert analysis by the interpreting cardiologist, but rather work synergistically by combining the cardiologist's expertise with the software's capability,” he said.

Researchers at the Medical University of South Carolina compared evaluations of five observers with varying levels of experience. The COR Analyzer “improves reader performance for diagnosing coronary artery stenosis, especially for inexperienced readers at the per patient level,” said Joseph Schoepf, M.D., professor of radiology and cardiology and director of cardiovascular imaging at the university.

In the study, the readers of different experience levels evaluated CTA studies in 50 patients and then re-evaluated the studies three months later with the COR Analyzer. The analyses were compared with quantitative catheter angiography. Inexperienced readers’ initial interpretations averaged 86 percent on a per-patient basis and improved to 100 percent with the COR Analyzer. For intermediate and expert readers, the sensitivity remained at 93 percent and 96 percent, respectively.

For more information: www.rcadia.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now